Journal of International Oncology

Journal of International Oncology››2019,Vol. 46››Issue (10): 617-619.doi:10.3760/cma.j.issn.1673-422X.2019.10.010

Previous ArticlesNext Articles

Application of CDK4/6 inhibitors in the treatment of hormone receptorpositive breast cancer

Mo Qiuping1，2, Chen Yiding1, Wang Xiaochen1，2

  1. 1Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; 2Department of Breast Surgery, Zhejiang Provincial People′s Hospital, Hangzhou 310014, China

  • Online:2019-10-08Published:2019-12-22
  • Contact:Wang Xiaochen, Email: wangxiaochen@zju.edu.cn E-mail: wangxiaochen@zju.edu.cn
  • Supported by:

    Natural Science Foundation of Zhejiang Province of China (LY19H160056)

PDF

281

Abstract:

With roles of blocking cell proliferation, cyclindependent protein kinase (CDK) 4/6 inhibitors are effective and safe complementary therapies for hormone receptorpositive breast cancer. CDK4/6 inhibitors combined with endocrine therapy significantly improve the prognosis of patients with advanced or metastatic breast cancer, especially those with endocrine resistance. Indications for CDK4/6 inhibitors are also expected to broaden into earlystage breast cancer. However, mechanisms of resistance of CDK4/6 inhibitors remain elusive.

Key words:

Breast neoplasms,Receptors, estrogen,Cyclindependent kinases,Therapeutics